Clinical and Experimental Medicine

, Volume 19, Issue 1, pp 115–120 | Cite as

Serum histamine and acetylcholine variations as new noninvasive biochemical markers in staging of experimental hepatocellular carcinoma

  • Nabil M. Abdel-HamidEmail author
  • Amer Hasan Abdullah
Original Article


Angiogenesis is a major prerequisite for hepatocellular carcinoma (HCC) development and progression. The present study aims to assess the potential role of two endogenous regulators of angiogenesis histamine (His) and acetylcholine (Ach), as possible biochemical markers for staging of HCC. Five groups of rats were used in this study: a control healthy group (I), another 4 intoxicated groups used for the induction of HCC with a high dose of diethyl nitrosamine (DENA, 200 mg/kg, single I.P. dose), (II, III, IV, and V). Groups II, III, IV, and V were killed following 8, 16, 24, and 32 weeks after DENA injection, respectively. Serum level of His and Ach was estimated using high-performance liquid chromatography technique coupled with diode array detector (HPLC–DAD), and alpha-fetoprotein (AFP) was measured using ELISA technique along with liver histological examination for all groups. Progression of HCC was estimated by histopathological examination. The results exhibited prominent increase in serum His and Ach levels during the early stages of HCC in group II, III in comparison with the control, and then His serum level declined to the normal level during the last stage of HCC development (group V).However, Ach elevation continued. AFP serum level showed marked increase, till 32 weeks after hepatocarcinogenesis. The decreased histamine level, combined to elevated AFP, indicates an early stage, while continued elevation of Ach with decreased His levels indicates a later stage of HCC. The combination of these two neurotransmitters to AFP may contribute to a noninvasive biochemical staging for HCC.


Hepatocellular carcinoma Histamine Acetylcholine AFP Staging 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All the animal experiments were conducted in accordance with the guide for the care and use of laboratory animals of the Faculty of Pharmacy, Kafrelsheikh University, Egypt.

Informed consent

The experiment is not a clinical study, so not applicable.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Yu MC, Yuan J-M, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14(8):703–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32(1):111–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Khattab MA, Eslam M, Sharwae MA, Hamdy L. Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000–2008. Am J Infect Control. 2010;38(8):640–1.PubMedCrossRefGoogle Scholar
  5. 5.
    Hassan MM, Zaghloul AS, El-Serag HB, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol. 2001;33(2):123–6.PubMedCrossRefGoogle Scholar
  6. 6.
    El-Zayadi A-R, Badran HM, Barakat E, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol WJG. 2005;11(33):5193–8.PubMedGoogle Scholar
  7. 7.
    Freedman LS, Edwards B, Ries L, Young J. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER, 2006.Google Scholar
  8. 8.
    Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014.Google Scholar
  9. 9.
    Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci. 2002;99(24):15584–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Abdel-Hamid M. Priority considerations in early laboratory diagnosis of hepatocellular carcinoma. IJIB. 2008;3(3):196–201.Google Scholar
  11. 11.
    Abelev G, Perova S, Khramkova N, Postnikova Z, Irlin I. Production of embryonal [alpha]-globulin by transplantable mouse hepatomas. Transplantation. 1963;1(2):174–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Nagasue N, Inokuchi K, Kobayashi M, Saku M. Serum alpha-fetoprotein levels after hepatic artery ligation and postoperative chemotherapy. Correlation with clinical status in patients with hepatocellular carcinoma. Cancer. 1977;40(2):615–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol WJG. 2006;12(8):1175–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet. 2002;359(9319):1734–9.CrossRefGoogle Scholar
  16. 16.
    Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs. 2008;19(7):655–71.PubMedCrossRefGoogle Scholar
  17. 17.
    de Esch IJ, Thurmond RL, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci. 2005;26(9):462–9.PubMedGoogle Scholar
  18. 18.
    Coruzzi G, Adami M, Pozzoli C. Role of histamine H4 receptors in the gastrointestinal tract. Front Biosci (Schol Ed). 2012;4:226–39.CrossRefGoogle Scholar
  19. 19.
    Hegyesi H, Darvas Z, Laszlo V, et al. Retinoic acid enhances histamine content and H1 receptor expression in human neuroblastoma cell line Paju. Anticancer Res. 2004;24(3A):1657–64.PubMedGoogle Scholar
  20. 20.
    Hill S, Ganellin C, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev. 1997;49(3):253–78.PubMedGoogle Scholar
  21. 21.
    Kahlson G, Rosengren E. New approaches to the physiology of histamine. Physiol Rev. 1968;48(1):155–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Zimmermann AS, Burhenne H, Kaever V, Seifert R, Neumann D. Systematic analysis of histamine and N-methylhistamine concentrations in organs from two common laboratory mouse strains: C57Bl/6 and Balb/c. Inflamm Res. 2011;60(12):1153–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Lampiasi N, Azzolina A, Montalto G, Cervello M. Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp Mol Med. 2007;39(3):284–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Medina MA, Quesada AR, de Castro IN, Sánchez-Jiménez F. Histamine, polyamines, and cancer. Biochem Pharmacol. 1999;57(12):1341–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Pós Z, Hegyesi H, Rivera ES. Histamine and cell proliferation. Histamine: biology and medical aspects. 1st ed. Budapest: SpringMed Publishing Ltd; 2004. p. 199–217.Google Scholar
  26. 26.
    Zhao Y, Wang X, Wang T, et al. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology. 2011;53(2):493–503.PubMedCrossRefGoogle Scholar
  27. 27.
    Nie H, Cao Q, Zhu L, et al. Acetylcholine acts on androgen receptor to promote the migration and invasion but inhibit the apoptosis of human hepatocarcinoma. PloS one. 2013;8(4):e61678.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Abdel-Hamid NM, Shehata DE, Abdel-Ghany AA, Ragaa A, Wahid A. Serum serotonin as unexpected potential marker for staging of experimental hepatocellular carcinoma. Biomed Pharmacother. 2016;83:407–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Bhattacharya S, Chatterjee M. Protective role of Trianthema portulacastrum against diethylnitrosoamine-induced experimental hepatocarcinogenesis. Cancer Lett. 1998;129(1):7–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Pitot HC, Barsness L, Goldsworthy T, Kitagawa T. Biochemical characterisation of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature. 1978;271(5644):456–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Basozabal I, Gomez-Caballero A, Diaz-Diaz G, et al. Rational design and chromatographic evaluation of histamine imprinted polymers optimised for solid-phase extraction of wine samples. J Chromatogr A. 2013;1308:45–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Bach B, Le Quere S, Vuchot P, Grinbaum M, Barnavon L. Validation of a method for the analysis of biogenic amines: histamine instability during wine sample storage. Anal Chim Acta. 2012;732:114–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Önal A. A review: current analytical methods for the determination of biogenic amines in foods. Food Chem. 2007;103(4):1475–86.CrossRefGoogle Scholar
  34. 34.
    Francis H, Onori P, Gaudio E, et al. H3 histamine receptor-mediated activation of protein kinase Cα inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res. 2009;7(10):1704–13.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Medina V, Croci M, Crescenti E, et al. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther. 2008;7(1):28–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Cianchi F, Cristina Vinci M, Masini E. Histamine in cancer: the dual faces of the coin. Cancer Biol Ther. 2008;7(1):36–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Tanimoto A, Matsuki Y, Tomita T, et al. Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. Pathol Int. 2004;54(6):408–12.PubMedCrossRefGoogle Scholar
  38. 38.
    Yatsunami K, Fukui T, Ichikawa A. Molecular biology of l-histidine decarboxylase. Yakugaku zasshi: J Pharm Soc Jpn. 1994;114(11):803–22.CrossRefGoogle Scholar
  39. 39.
    Hegyesi H, Somlai B, Varga VL, et al. Suppression of melanoma cell proliferation by histidine decarboxylase specific antisense oligonucleotides. J Investig Dermatol. 2001;117(1):151–3.PubMedCrossRefGoogle Scholar
  40. 40.
    Graff L, Frungieri M, Zanner R, et al. Expression of histidine decarboxylase and synthesis of histamine by human small cell lung carcinoma. Am J Pathol. 2002;160(5):1561–5.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Garcia-Caballero M, Neugebauer E, Rodriguez F, De Castro IN, Vara-Thorbeck C. Histamine synthesis and content in benign and malignant breast tumours. Its effects on other host tissues. Surg Oncol. 1994;3(3):167–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Chanda R, Ganguly A. Diamine-oxidase activity and tissue di-and poly-amine contents of human ovarian, cervical and endometrial carcinoma. Cancer Lett. 1995;89(1):23–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Garcia-Caballero M, Neugebauer E, Campos R, de Castro IN, Vara-Thorbeck C. Increased histidine decarboxylase (HDC) activity in human colorectal cancer: results of a study on ten patients. Agents Actions. 1988;23(3–4):357–60.PubMedCrossRefGoogle Scholar
  44. 44.
    Fisher ER, Sass R, Watkins G, Johal J, Fisher B. Tissue mast cells in breast cancer. Breast Cancer Res Treat. 1985;5(3):285–91.PubMedCrossRefGoogle Scholar
  45. 45.
    Graham RM, Graham J. Mast cells and cancer of the cervix. Surg Gynecol Obstet. 1966;123(1):3–9.PubMedGoogle Scholar
  46. 46.
    Fisher ER, Paik S, Rockette H, et al. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol. 1989;20(2):159–63.PubMedCrossRefGoogle Scholar
  47. 47.
    Cervello M, Foderà D, Florena AM, et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol. 2005;11(30):4638.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Zhao Y. The oncogenic functions of nicotinic acetylcholine receptors. J Oncol. 2016;2016:9650481.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of PharmacyKafrelsheikh UniversityKafr El SheikhEgypt
  2. 2.Department of Biochemistry, Faculty of PharmacyAl-Farahidi UniversityBaghdadIraq
  3. 3.Department of Chemistry, Faculty of ScienceAl-Mustansiryah UniversityBaghdadIraq

Personalised recommendations